AC Immune SA (ACIU), Thursday announced positive interim safety and efficacy results from the Phase 2 VacSYn trial of anti-alpha-synuclein active immunotherapy ACI-7104.056 in early Parkinson's disease.
The findings noted that ACI-7104.056 induced a robust antibody response against the immunizing a-syn target antigen with a 100 percent responder rate.
Also, the stabilization of disease-relevant biomarkers in the central nervous system, suggests slowing of Parkinson's disease pathology, with potential disease modification, the company stated.
Moreover, the consistent signs of efficacy, combined with the continuing strong safety record, further highlight ACI-7104.056's potential to treat Parkinson's disease.
Based on these findings, the company aims to seek regulatory feedback on an ACI-7104.056 clinical development plan.
Meanwhile, AC Immune expects final data from Part 1 of the trial in mid-2026.
ACIU closed trading at $2.54, down 8.63 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.